BioNTech SE (22UA) Stock Price & Analysis
22UA Stock Chart & Stats
- Day’s Range
- EUR 78.75 - EUR 80.75
- 52-Week Range
- EUR 68.30 - EUR 105.70
- Previous Close
- EUR 79.15
- Volume
- 48.95K
- Average Volume (3M)
- 25.67K
- Market Cap
- EUR 19.77B
- Enterprise Value
- EUR 6.84B
- Total Cash (Recent Filing)
- EUR 9.74B
- Total Debt (Recent Filing)
- EUR 315.97M
- Price to Earnings (P/E)
- ―
- Beta
- 0.86
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 0.67
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet
Very low leverage and substantial equity give BioNTech considerable capacity to fund research, absorb clinical setbacks, and pursue strategic opportunities without relying heavily on external financing. This financial flexibility supports continued investment while the company transitions beyond COVID-19 revenue.
Late-stage Oncology Pipeline
Multiple oncology assets are progressing into pivotal development, increasing the possibility of future product diversification beyond Comirnaty. Positive efficacy signals across several tumor types and mechanisms strengthen the pipeline’s strategic value, although eventual approval and commercialization remain dependent on trial outcomes.
Strategic Combination Partnerships
The Gilead collaboration broadens pumitamig’s development strategy by pairing it with an established antibody-drug conjugate in a contemporary treatment setting. Partner-supplied therapy and a global pivotal trial can expand clinical reach, validate the platform, and support future commercial optionality.
Bears Say
COVID Revenue Dependence
BioNTech remains materially exposed to the normalization of COVID-19 vaccination demand, creating a lower and less predictable revenue base than during the pandemic. Continued weakness in vaccine orders can pressure funding capacity and increase reliance on collaboration payments while oncology products mature.
Persistent Operating Losses
The current revenue run-rate does not yet cover BioNTech’s substantial R&D and SG&A investment, producing sizable losses despite strong gross margins. If this mismatch persists, accumulated losses may reduce equity over time and make successful pipeline execution increasingly important to restoring sustainable profitability.
Clinical Execution Setbacks
Stopping an individualized mRNA cancer trial after an unfavorable survival imbalance weakens confidence in part of the oncology portfolio and reduces one potential future revenue opportunity. The setback also highlights development risk as BioNTech works to translate promising platform science into reliable clinical benefits.
BioNTech SE News
22UA FAQ
What was BioNTech SE’s price range in the past 12 months?
What is BioNTech SE’s market cap?
When is BioNTech SE’s upcoming earnings report date?
How were BioNTech SE’s earnings last quarter?
Is BioNTech SE overvalued?
Does BioNTech SE pay dividends?
What is BioNTech SE’s EPS estimate?
How many shares outstanding does BioNTech SE have?
What happened to BioNTech SE’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioNTech SE?
What is the TipRanks Smart Score and how is it calculated?
BioNTech SE Stock Smart Score
Company Description
BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin
- Employees
- 7,807
- Website
- www.biontech.com/de/de/home.html
- Address
- An der Goldgrube 12, Mainz, RP, 55131, DE
BioNTech SE (22UA) Earnings & Revenues
22UA Company Deck
22UA Earnings Call
Earnings Call SentimentNeutral
The call balances meaningful near‑term financial headwinds (sharp Q2 revenue decline, guidance reduction, increased SG&A and some timeline pushes) against substantial clinical and strategic progress: multiple encouraging Phase II signals (pumitamig, gotistobart), initiation of a Phase III for LCD, continued advancement of mRNA oncology programs, a strong cash position (EUR 16.6B) and active capital return. The pipeline momentum and capital strength mitigate short‑term revenue weakness, but the quarter highlights both execution progress and clear near‑term commercial challenges.
View all DE:22UA earnings summaries22UA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 2 | 0 | 10 |